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Objectives. Hepatitis B virus (HBV) was believed to have minimal impact on pregnancy outcomes apart from the risk of perinatal
transmission. In more recent years, there have been reports of adverse associations, most consistently preterm birth (PTB), but this
is in the context of high rates of caesarean section. The aim of this study was to explore the association of HBV on pregnancy
outcomes in marginalized, low-income populations on the Myanmar-Thailand border. Methods. HBsAg positive (+) point of
care rapid detection tests results were confirmed by immunoassays. Women with a confirmed HBsAg status, HIV- and syphilis-
negative at first antenatal care screening, singleton fetus and known pregnancy outcome (Aug-2012 to Dec-2016) were included.
Logistic regression analysis was used to evaluate associations between HBV group (controls HBsAg negative, HBsAg+/HBeAg-
, or HBsAg+/HBeAg+) and pregnancy outcome and comorbidity. Results. Most women were tested, 15,046/15,114 (99.6%) for
HBV. The inclusion criteria were not met for 4,089/15,046 (27.2%) women due mainly to unavailability of pregnancy outcome and
nonconfirmation of HBsAg+. In evaluable women 687/11,025 (6.2%) were HBsAg+, with 476/11,025 (4.3%) HBsAg+/HBeAg- and
211/11,025 (1.9%) were HBsAg+/HBeAg+. The caesarean section rate was low at 522/8,963 (5.8%). No significant associations were
observed between pregnancy comorbidities or adverse pregnancy outcomes and HBV status. Conclusions. The results highlight the
disease burden of HBV inwomen on theMyanmar-Thailand border and support original reports of a lack of significant associations
with HBsAg+ irrespective of HBeAg status, for comorbidity, and pregnancy outcomes in deliveries supervised by skilled birth
attendants.
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1. Introduction
Hepatitis B virus (HBV) infection is hyperendemic in South-
east Asia. It is assumed that about 75-80% of the estimated
240 million HBV carriers globally live in this region [1].
In endemic areas in Southeast Asia and Africa, where the
most significant route of transmission is from mother to
child (MTCT) or from child to child, up to 90% of infected
persons have a chronic course [2, 3]. In mothers who are
HBeAg positive (+) and at highest risk of transmitting HBV,
Hepatitis B immunoglobulins (HBIG) should be routinely
provided if women give birth or in the case of homebirth the
infant should be presented to a clinic where this specialized
vaccination is available before 72 hours of life [4, 5]. However,
this prophylactic regimen is often not given in low-income
countries (LIC) because of cost, complexity of production,
and need for a reliable cold chain [6]. Health care systems
in LIC struggle to respond to the significant burden of
communicable infections in pregnancy and routine HBV
testing is not always available [7].
For many years it has been thought that maternal HBV
infection had no influence on pregnancy outcomes [8],
but published evidence particularly from the last 5 years
suggests there may be an impact of HBsAg+ irrespective of
HBeAg status on preterm birth, among other outcomes [9–
14]. Preterm birth (PTB) has been highlighted as a major
finding in three [10, 13, 14] of these publications. While
there is theoretical evidence to support an increased risk of
PTB from chronic liver disease due to increased cytokine
production from inflammation [15], the PTB data remains
largely observational and at risk of bias. Sources of bias
could include inability to control use of other (social) drugs,
other (subclinical) infections, e.g., Hepatitis C virus, poor
gestational age assessment, and obstetrician preference for
caesarean section [16], a known iatrogenic risk factor for PTB.
The leading countries contributing to data on pregnancy out-
come according to HBV status are the USA and Europe who
have lowHBV prevalence and China with amoderate to high
HBVprevalence; USA andChina have high rates of caesarean
section [17]. Controlling the indication for caesarean section
in data extraction for systematic review and meta-analysis
can be problematic as country policy and local hospital prac-
tice may not confer. HBsAg+, irrespective of HBeAg status,
was associated with miscarriage in one study [11] where more
than 20,000 women were registered since the first trimester.
Other studies have not found associations between HBsAg+
(irrespective of HBeAg status) and pregnancy outcomes and
pregnancy morbidity including premature rupture of mem-
branes, preeclampsia, gestational diabetes mellitus (GDM),
increased risk of prematurity, lower birth weight, small- or
large for gestational age or antepartum hemorrhage [10–12].
A high burden of HBV (8.3%) infection in refugees and
migrant pregnant women on the Myanmar-Thailand border
as well as factors associated with infection (age over 25 years
and Karen heritage) for the period of August 2012 and April
2014 has been reported [18]. In this retrospective study we
aimed to examine the association of HBV infection with
coinfection, pregnancy morbidity, and pregnancy outcomes,
including caesarean section, by expanding upon the previous
cohort presenting data from August 2012 to December 2016,
and previously unpublished data on pregnancy outcomes.
2. Methods
2.1. Study Design. This is a retrospective cohort study of
refugee and migrant women registered at antenatal clinics on
the Myanmar-Thailand border and screened for HBV.
2.2. Setting. Shoklo Malaria Research Unit (SMRU) provides
humanitarian health care for marginalized populations in
north western Thailand on the border with Myanmar, with
a focus on maternal and child health. At the time of data
collection, antenatal care (ANC) and birthing services were
available at three sites: twomigrant sites,MawkerThai (MKT)
and Wang-Pha (WPA), and one refugee site, Maela (MLA)
camp.Three decades of maternal and child health care on the
Thailand-Myanmar border have resulted in significant trust
in the services provided by SMRU among the local popu-
lation. Karen/Kayin state in eastern Myanmar is a difficult
geographical setting—roads become impassable in the rainy
season making it impossible to reach clinics [19]. Attendance
at ANC is voluntary and uptake is high. In the migrant popu-
lation attendance and delivery have continued to increase, in
part because access in rural areas tomaternal and child health
services provided in Karen and Burmese language is limited,
and health care in Myanmar and Thailand is associated with
significant household expenditure [20, 21]. In rural eastern
Myanmar up to 3/4 women give birth at home [22].
Antiretroviral treatment of HBV in pregnancy is not
supported by the government in Myanmar or in Thailand in
pregnancy, and while it could be obtained from out of pocket
expenses this would be beyond the means of this marginal-
ized population. Trust in government services in Myanmar is
low with significant out-of-pocket expenditure, so most poor
rural populations avoid seeking care at tertiary hospitals [23].
2.3. Participants. Participants were refugee and migrant
women registered at SMRU ANC on theThailand Myanmar.
2.4. Routine ANC and Birth Procedures. Routine counseling
and screening commenced in MKT on 08-Aug-2012, in
WPA on16-Aug-2012, and in MLA on 28-Aug-2012. The
HBV test was offered at the first ANC visit along with
screening for other infections, Human Immunodeficiency
Virus (HIV), syphilis, common tropical infections, malaria,
and soil transmitted helminths [22].Women that test positive
for HBV infection do not get treated with antiviral therapy.
Malaria smears were done every twoweeks in themigrant
setting and for the first three visits for refugees and at any time
if the woman complained of malaria symptoms, had a fever,
or had preterm labor. All women routinely received prophy-
lactic supplements including ferrous sulphate 200 mg daily,
folic acid 5mg per week, and vitamin B1 100mg daily. Haema-
tocrit (HCT) was measured at each visit, with most women
checked at least four times by delivery. Any HCT value < 30%
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was defined as anemia in pregnancy. General maternal exam-
ination was performed according to a set schedule, including
weight, blood pressure, and fundal height. In women with
hypertension (BP ≥140/90 mmHg), proteinuria was tested at
least twice 6 hours apart to differentiate pregnancy induced
hypertension from preeclampsia. Eclampsia was defined by
hypertension and convulsions. Low (<18.5 kg/m2), normal
(18.5-23 kg/m2), and high (≥23 kg/m2) BMI were defined
usingWHO standards for Asian populations [24]. All women
were providedwith anultrasound assessment at the firstANC
visit, determining the number of fetus as well as enabling
the estimation of gestational age (EGA). Gestational Diabetes
Mellitus (GDM) screening with 75g oral glucose tolerance
test was based on risk factors developed for this population
[25]. Miscarriage included loss of the pregnancy before 28
weeks. Preterm birth (PTB) was delivery before 37 weeks’
gestational age and size for gestational age was determined
using international standards [26]. Women were encouraged
to deliver at SMRU clinics with skilled birth attendants [27].
Women requiring caesarean section were referred out to the
nearest Thai Public Hospital; the majority of these are for
emergencies only or when booked, for clearly documented
pathologies such as placenta praevia. Caesarean section by
maternal request or without a medical or obstetric indication
is not available. Every newborn had a physical examination
conducted by trained clinical staff with results recorded on a
standard reporting form [28].
2.5. Laboratory Methods. Initial screening for HBV was
performed using a rapid diagnostic test (RDT, Pacific Biotech,
Thailand) with a reported sensitivity of 100% (63.1-100%)
and specificity of 100% (98.9-100%) [29]. The high sensitivity
and specificity are not consistent with the false positive rate
of 3.1% (95% CI 1.7- 5.4) in pregnant women previously
reported by SMRU [18]. Serum from the women with RDT
HBsAg-positive was sent for verification using the HBsAg
electrochemiluminescence immunoassay (ECLIA) on Cobas
e immunoassay analyzer (Roche Diagnostics, Indianapolis,
USA) and from June 2014 with the Chemiluminescence
immunoassay (CLIA) method (Unicel DxI1800, Beckman
Coulter). This was conducted independently at the local
tertiary referral provincial hospital in Thailand (the assay
has been CE marked according to Directive 98/79/EC). The
HBeAg electrochemiluminescence immunoassay was also car-
ried out in the external laboratory on Cobas e immunoassay
analyzer (Roche Diagnostics, USA).
HIV was screened using a one-step Anti-HIV (1&2) Tri-
Line Test and confirmed by a second test if the first test was
reported as reactive, syphilis by VDRL and TPHA, malaria
by microscopy of Giemsa stained thick blood smear, and
declared negative if no parasites were detected in 200 high
powered fields, and soil transmitted helminths from fecal
samples were processed the same day using the formalin
concentration method for detection of helminth eggs [30].
2.6. Inclusion and Exclusion Criteria. All women who
attended the ANC of SMRU starting 16 August 2012 and had
a delivery outcome by 31 December 2016 were screened for
inclusion in this analysis (Figure 1). Women with a singleton
fetus, confirmation of positive HBsAg RDT, who screened
negative for HIV and syphilis, and had a known outcome of
pregnancy were included. In this highly mobile population
approximately 20% of women register to antenatal care but
move, usually for work, before the outcome of pregnancy is
known. Low burden of HIV 17/3,599 (0.47%, 95% CI 0.30-
0.76) and syphilis 14/3,592 (0.39%, 95% CI 0.23-0.65) has
previously been reported in pregnant women in this area
[31]. There was no data on Hepatitis C infections or other
sexual transmitted diseases. Rates of multiple pregnancies in
this area are low at approximately 1% and there is no assisted
fertility treatment.
2.7. Statistical Analysis. Data were analyzed using SPSS ver-
sion 23. Demographic characteristics of the three groups
(controls, HBsAg+/HBeAg- and HBsAg+/HBeAg+) were
compared using the Chi-squared test for categorical variables
and the Student’s t-test or Mann–Whitney-U test for contin-
uous data.
The Pearson Chi-squared test was used to examine the
association of HBV infection and comorbidity and HBV
infection and pregnancy outcome: computing crude odds
ratio (OR) with 95% confidence intervals (CIs). Logistic
regressionmodels were used to study the association between
HBV infection and comorbidity andHBV infection and preg-
nancy outcomes. Bonferroni correction for multiple testing
was performed for p<0.05. The variables were checked for
confounding and effectmodification for the stated pregnancy
outcomes.
Reported demographic variables included categorical:
gravidity, parity, BMI, height; dichotomous: age younger than
25 years, Karen ethnicity, migrant status, literacy, smoking,
attendance of ANC in the first trimester, underweight any-
time in pregnancy and in first trimester (BMI as a proxy
for prepregnancy weight, and in women with gravidity >1 a
previous history of miscarriage and PTB). Coinfections dur-
ing pregnancy included malaria, nonmalaria febrile illnesses
during pregnancy (temperature of >37.5 degrees Celsius),
and soil transmitted helminths (including Hookworm as
Necator americanus and Ancylostoma duodenale ova which
cannot be differentiated by microscopy, Ascaris lumbricoides
(roundworm) or Trichuris (T.) trichiura (whipworm)). Preg-
nancy relatedmorbidity included anemia, pregnancy induced
hypertension, preeclampsia and eclampsia and GDM. Avail-
able pregnancy outcomes included maternal death, miscar-
riage, delivery, gestational age, PTB, stillbirth, congenital
abnormality, birthweight, small for gestational age (SGA),
large for gestation age (LGA), delivery by caesarean section,
and neonatal death. For analysis related to birth weight,
only liveborn, congenitally normal infants with a valid birth
weight within 72 hours after birth were included.
2.8. Ethics. This study was approved by the local Tak
Community Advisory Board (20171028-TCAB-13), Oxford
Tropical Research Ethics Committee (OXTREC 28-09), and
the Chiang Mai University Research Ethics Committee
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New ANC registration at screening commencement 
16 August 2012 and pregnancy outcome by 31 Dec 2016 
n=15,114
HBV confirmed, singleton pregnancy n=11,229
Unknown pregnancy outcome n=3,531/15,046 (23.5%)
Multiple pregnancy n=125/15,046 (0.8%)
HBsAg-
HBeAg-
n=10,338
HBsAg+
HBeAg+
n=211
HBsAg+
HBeAg-
n=476
No HBV screening done n=68/15,114 (0.4%)
HBV screening by RDT n=15,046
Syphilis+ n=47/11,229 (0.4%); screening not done n=93/11,229 (0.8%) 
HIV+ n=50/11,229 (0.4%); screening not done n=14/11,229 (0.1%)
HBsAg+ and HBeAg not confirmed n=161/11,390 (1.4%)
HBV screening by RDT, singleton pregnancy n=11,390
HBV confirmed, singleton pregnancy, HIV- and Syphilis- n=11,025
Figure 1: Inclusions and exclusions for the analyses.
(FAM-2560-05195).The patient datawere anonymized before
accessing and entering them for this study.
3. Results
The majority of women who presented to SMRU ANC
between August 2012 and December 2016, 15,046/15,115
(99.6%), were tested for HBV infection (Figure 1). The
inclusion criteria were not met for 4,089/15,046 (27.2%) of
women with the two main exclusions being unavailability of
pregnancy outcome (3,531/4,089women, 86.4%), an expected
result in this highly mobile population, and nonconfirmation
of HBsAg+ RDT (161/4,089, 3.9%).
There were differences in the baseline characteristics
of women who were included and excluded (n=4,089) (S2
Table). Unavailability of pregnancy outcomes occurred in
each trimester as seen by trimester of last antenatal visit (S2
Table) and included women who left the catchment area for
work or to deliver with more family support in their home
town or from a pregnancy outcome elsewhere. It is more
difficult for migrant women and visitors to the refugee camp,
especially those whose residence is in Myanmar, to cross
the border (which is a river) to reach the birthing services,
than for women residing at the camp who are within walking
distance from the clinic (S2 Table). No significant difference
in the proportion of HBsAg+ was observed for included
687/11,025 and excluded cases 250/3,802 (6.6%), p=0.464 (S2
Table).
The only differences in the comparisons of demographic
(S3 table) and delivery characteristics (S4 Table) for HBsAg+
confirmed (included women) and HBsAg+ unconfirmed
(excluded women) were for status where the proportion of
migrants was higher and first trimester attendees lower, in
excluded women. For HBeAg+ women who were included
and excluded significant differences were observed in the
mean age of excluded women, which was slightly older, and
ethnicity, as excluded women were less likely to be Karen (S5
Table).
Among the 11,025 women included in the final analyzes,
the proportion of HBsAg+ was 687/11,025 (6.2%, 95% CI 5.7-
6.7). There were 476/11,025 (4.3%) of the women grouped as
HBsAg+/HBeAg- and 211/11,025 (1.9%) asHBsAg+/HBeAg+.
3.1. Demographic Characteristics. The characteristics of eli-
gible pregnant women according to HBV infection status
are presented in Table 1. Women with HBsAg+/HBeAg-
and HBsAg+/HBeAg+ differed from controls and from each
other. A significantly higher proportion of women with
HBsAg+/HBeAg- were of older age, whereas those with
HBsAg+/HBeAg+ were of younger age. Given these signifi-
cant differences in age, variations in obstetric (gravidity, par-
ity, and primigravida) and BMI characteristics (overweight)
are not unexpected (Table 1).
A higher proportion of women with Karen heritage had
HBV infection, but a higher proportion of refugees were
HBsAg+/HBeAg- while migrants were HBsAg+/HBeAg+
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(Table 1). There was no significant difference between the
groups for literacy, the proportion of first ANC visits in
first trimester, maternal height, and in multigravid women,
a history of previous abortion, and PTB.
3.2. Pregnancy Comorbidity. The proportion of coinfections
(malaria, soil transmitted helminths) detected by screening
and pregnancy related morbidity that occurred over the
course of gestation (anemia, pregnancy induced hyperten-
sion, eclampsia or preeclampsia, or GDM were similar
between groups) were similar between groups (Table 2).
Nonmalaria febrile illness was lower in the HBsAg+/HBeAg-
compared to the control group (OR 0.53, 95% CI 0.31-0.89,
p=0.017).
For individual species of soil transmitted helminths,
the proportion of Hookworm and Trichuris Trichiura were
similar by HBV status but there was a higher, nonsignificant
proportion of Ascaris lumbricoides infection in women with
HBsAg+/HBeAg+: 36/177 (20.3%) compared to controls
1,245/7,8201 (15.2%) OR 1.43 (0.98-2.07), p= 0.061.
In a logistic regression model, risk factors associated with
HBsAg+/HBeAg+ compared to controls included Ascaris
lumbricoides infection aOR 1.59 (1.08-2.35), p=0.020; age less
than 25 years aOR 2.64 (1.91-3.65), p<0.001; migrant status
aOR 1.57 (1.12-2.19); p=0.008, and Karen heritage aOR 1.79
(1.25-2.56), p=002.
3.3. Pregnancy Outcomes. The proportion of maternal mor-
tality was highest in the control group compared to the
HBsAg+/HBeAg- and HBsAg+/HBeAg+ groups (Table 3).
In this cohort HBV was not associated with an increased
risk of miscarriage, PTB, stillbirth, congenital abnormality,
or neonatal death, and HBV did not have a negative effect on
mean birthweight or SGA.
The proportion of women who delivered by caesarean
sectionwas low: 522/8,963 (5.8%).Therewas a higher propor-
tion of women in the HBsAg+/HBeAg- group who delivered
by caesarean section (34/379 (9.0%) compared to controls
480/8,417 (5.7%)with anOR 1.61 (95%CI 1.13-2.30), p= 0.008)
on univariate analysis, but, with Bonferroni correction for
multiple testing, the difference was no longer statistically
significant, p=0.064 (Table 3).
4. Discussion
This review including more than 11,000 women from a low-
income setting does not support an increased risk of adverse
birth outcomes for those women with HBsAg+ irrespective
of HBeAg status compared to controls when pregnancy out-
comes were supervised by skilled birth attendants. In multi-
gravid women who attended ANC from the first trimester,
there was no increased risk of miscarriage with HBV, which
differs from recent previous reports [11, 32]. Pregnancy asso-
ciated morbidity (GDM, eclampsia and preeclampsia) and
outcomes of stillbirth and PTBwere also not significantly dif-
ferent by HBV status in this cohort [33, 34]. Careful interpre-
tation of obstetric outcomes is required due to the linear asso-
ciation of HBV infection with age and with age and gravidity.
The absence of adverse pregnancy outcomes observed
here and reported elsewhere could be related to the chronic
character of HBV infection [35]. In this population we
expect that most of the women will have acquired their
HBV infection preconceptually or during childhood. The ear-
lier publications on HBV and adverse pregnancy outcomes
emphasized poor outcomes with acquisition of acute HBV
infection in late pregnancy [36, 37]. For the women in this
population with an HBsAg+ and especially HBeAg+ status,
the dominant risk of HBV infection in pregnancy is the
unmeasured risk of transmission of infection from mother
to child. This is a problem in LIC with high HBV burden as
the expanded program of immunization can be suboptimal,
HBIG is usually not available, andwomen often labor without
skilled birth attendance at home [6]. There is currently a
shift towards consideration of alternative strategies to relying
on vaccination and HBIG to interrupt transmission, such as
antiretroviral therapy with tenofovir [6].
4.1. Hepatitis B Virus Burden. Although HBV is recognized
as being highly prevalent in Southeast Asia, in this sample
of pregnant women there was a proportion of HBsAg+
of 6.2% (95%CI 5.7-6.7) with almost one-third who were
also HBeAg+ (30.7%; 95%CI 29.8-31.6). Comparison of
HBV prevalence between different countries revealed that
our estimates of HBV in Thailand are lower than those
reported for other low and middle income countries. An
Asian study among 3009 samples reported a prevalence of
HBsAg positivity of 9.4% with 121 Cambodians (10.8%), 54
Laotians (6.9%), and 107 from Myanmar (9.7%) [38]. In
high income countries the prevalence is much lower than
that reported for Asia; for instance, in northern America
and western Europe, the prevalence is between 1-2%. The
difference in prevalence with high income countries could be
due to a better implementation of the vaccination program
on top of the previous immunization of high risk groups
and lower population prevalence of HBV before vaccination
became available [39].This is further supported by the overall
decrease inHBVprevalence from 1990 to 2005 in younger age
groups [40, 41].
4.2. Pregnancy Coinfections. There was no significant associ-
ation between HBV and malaria, but the overall proportion
of women infected with malaria in this cohort was low. This
low level of malaria is expected given very active control
programs on both sides of the border in the study area
[42, 43]. There was a nonsignificant higher proportion of
A. Lumbricoides in women with HBsAg+/HBeAg+. It is
possible that HBsAg+/HBeAg+ contributes to a reduced
immune response to helminthic infection, or vice versa [44–
46]. Integration of screening and deworming should be
considered in studies considering ARV PMTCT of HBV in
areas with high rates of soil transmitted helminths in the
population [6, 44].
4.3. Limitations. The major limitation of this analysis is the
27.2% of women who booked at ANC but had unavailable
pregnancy outcome or no confirmation of the positive point
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of care rapid test result. Reassuringly there were no important
differences between included and excluded women and in
demographic and delivery outcomes of HBsAg confirmed
and unconfirmed women (S2–S4 Tables) reducing the risk
of bias in reported outcomes such as miscarriage and PTB.
Data needs to be considered in context and on the Thailand-
Myanmar border it is very unlikely that these marginalized
women were able to selectively choose more sophisticated
care for their HBV status or meet the out of pocket expendi-
ture for basic mother and child health care in Myanmar [23].
GDM screening employed a risk-factor based approach
due to cost constraints, so the prevalence is likely an under-
estimate. Only 4/5 of women provided stool samples, so
cautious interpretation of helminth data is required. Finally
only indirect markers (HBsAg and HBeAg) of HBV infection
were available.
In this as in other cohorts, the precise indication for
caesarean section was not available, potentially leading to
bias in pregnancy outcomes [17]. However, the indications
in this setting for caesarean section are for emergencies in
>90% of cases and booked cases have a significant pregnancy
related complication, such as placenta previa. The associa-
tions observed in this cohort are very similar to older reports
on HBV when caesarean section rates were much lower than
current reports [47].
5. Conclusions
Overall, the results highlight the disease burden of HBV in
women on the Myanmar-Thailand border. The mobility of
these populations is significant as one in four women did not
have their final pregnancy outcome at the clinic where they
registered and followed antenatal care. In births supervised by
skilled birth attendants, there were no significant associations
between HBsAg+ irrespective of HBeAg status for comorbid-
ity or for pregnancy outcomes.
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Supplementary Materials
Table S1. Reported associations of HBV and pregnancy out-
come from case control, systematic reviews, meta-analysis, and
large (>20,000) population based cohorts from the last 5 years.
Abbreviations (alphabetic order). Antepartum hemorrhage:
APH, adjusted Odds Ratio: aOR, birth weight: BW, Cae-
sarean Section: CS, Cohort (large >20,000 population based),
Congenital abnormality: CA, Eclampsia: EC, intrahepatic
cholestasis of pregnancy: ICP, large for gestational age: LGA,
low birth weight: LBW, meta-analysis: MA; Neonatal Jaun-
dice: NJ, Odds Ratio: OR, pooled Odds Ratio: pOR, pooled
Risk Ratio: pRR, Preeclampsia: Pre-EC, Pregnancy induced
hypertension (or gestational hypertension): PIH, Preterm
birth: PTB, Preterm rupture of membranous: PROM, Small
for gestational age: SGA, Stillbirth: SB, Systematic Review: SR.
Table S2. Characteristics of all women screened for hepatitis
B virus. Data are n (%) unless otherwise stated, 1p value of
10 Journal of Pregnancy
0.05was considered statistically significant. Table S3. Baseline
characteristics of the included and excluded pregnant women
with HBsAg confirmed and unconfirmed status. Data are n
(%), mean ± standard deviation (SD) (min-max); median
interquartile range [IQR] (min-max). Abbreviations. ANC:
antenatal clinic, BMI: body mass index, PTB: preterm birth.
1p value of 0.05 was considered statistically significant, and
2BMI if trimester at first ANC was trimester one, as a proxy
for prepregnancy weight. Table S4. Pregnancy outcomes in
HBsAg confirmed and HBsAg+ but unconfirmed women. Data
are n (%) unless otherwise stated. 1p value of 0.05 was consid-
ered statistically significant. Table S5. Baseline characteristics
of the included and excluded pregnant women with HBeAg
confirmed status. Data are n (%), mean ± standard deviation
(SD) (min-max); median interquartile range [IQR] (min-
max). Abbreviations. ANC: antenatal clinic, BMI: body mass
index, PTB: preterm birth. 1p value of 0.05 was considered
statistically significant, and 2BMI if trimester at first ANC
was trimester one, as a proxy for prepregnancy weight.
(Supplementary Materials)
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